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Soluble fibrinogen binding to the glycoprotein IIb- 
IIIa complex (integrin (wId3) requires platelet activa- 
tion. The intracellular mediator(s) that convert glyco- 
protein IIb-IIIa  into  an  active fibrinogen receptor have 
not been identified. Because the lipid composition of 
the platelet plasma membrane undergoes changes dur- 
ing activation, we investigated the effects of lipids on 
the fibrinogen binding properties of purified glycopro- 
tein IIb-IIIa. Anion exchange chromatography of lipids 
extracted from platelets exposed to thrombin or  other 
platelet agonists resolved an activity that increased 
fibrinogen binding to glycoprotein 1%-IIIa. A monoes- 
ter phosphate was important  for  activity,  and phospha- 
tidic acid coeluted with  the peak of activity. Purified 
phosphatidic acid dose-dependently promoted a spe- 
cific interaction between glycoprotein IIb-IIIa  and  fi- 
brinogen which  possessed  many but not all of the prop- 
erties of fibrinogen binding to activated platelets. 
Phosphatidic acid appeared  to  increase  the proportion 
of fibrinogen binding-competent glycoprotein IIb-IIIa 
complexes without altering  their  affinity  for  fibrino- 
gen. The effects of phosphatidic acid were  a  result of 
specific structural  properties of the lipid and  were not 
mimicked by other phospholipids. Lysophosphatidic 
acid, however, was a potent inducer of fibrinogen bind- 
ing to glycoprotein IIb-IIIa. These results demonstrate 
that specific lipids can affect fibrinogen binding to 
purified glycoprotein IIb-IIIa  and suggest that  the lipid 
environment has  the potential to influence fibrinogen 
binding to its receptor. 
The binding of the plasma protein fibrinogen to  the glyco- 
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protein IIb-IIIa (GP’ IIb-IIIa or aI&) complex mediates 
platelet aggregation (Phillips et al., 1988; Plow and Ginsberg, 
1989). GP IIb-IIIa exists as a Ca2+-dependent heterodimer 
(Brass et al., 1985; Fitzgerald and Phillips, 1985); each subunit 
is predicted to have a large extracellular domain, a single 
membrane-spanning region, and a short cytoplasmic tail 
(Poncz et aZ., 1987; Fitzgerald et al., 1987). Although the  GP 
IIb-IIIa complex is present on the surface of resting platelets, 
it serves as a fibrinogen receptor only after platelet  activation 
(Bennett  and Vilaire, 1979). 
GP  IIb-IIIa belongs to a family of cell surface receptors, the 
integrins, that  are composed of noncovalently associated a- 
and /3-subunits (Hynes, 1987). In addition to  their structural 
similarities, integrins  share several functional properties, in- 
cluding the ability to mediate cell to cell and cell to extracel- 
lular  matrix  interactions. A common feature of many mem- 
bers of the integrin family is their ability to bind proteins 
containing the tripeptide sequence Arg-Gly-Asp (RGD) 
(Ruoslahti and Pierschbacher, 1987). Fibrinogen binding to 
GP IIb-IIIa  can be inhibited by both RGD-containing  pep- 
tides (Plow et al., 1985) and  the synthetic peptide His-His- 
Leu-Gly-Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val (H12), corre- 
sponding to  the carboxyl-terminal segment of the y-chain of 
fibrinogen (Plow et al., 1984). Many integrins  constitutively 
bind ligands; however, accumulating evidence indicates that 
the binding activity of members of both the (Shimizu, 1990) 
and Pz (Wright and Meyer, 1986; Dustin and Springer, 1989) 
class of integrins may  be modulated by cellular activation,  in 
a manner similiar to  that of GP IIb-IIIa. 
Despite advances in delineating the  structure  and function 
of the  GP IIb-IIIa complex, little is known about the mecha- 
nisms by which GP IIb-IIIa acquires fibrinogen binding activ- 
ity  on the surface of activated platelets. Investigations of the 
mechanism of activation of GP IIb-IIIa have been hampered 
by the observation that, when removed from intact platelets, 
GP  IIb-IIIa does not possess the levels of fibrinogen binding 
observed in  activated  platelets. GP IIb-IIIa  in isolated platelet 
membranes (Phillips and Baughan, 1983), reconstituted in 
phospholipid vesicles (Parise and Phillips, 1985b), or ex- 
pressed recombinantly in a variety of cell types (Bodary e t  al., 
1989; O’Toole et al., 1991) cannot bind stoichiometric quan- 
tities of soluble fibrinogen. However, the capacity to bind 
fibrinogen is an intrinsic property of the receptor because 
certain GP IIIa-specific monoclonal antibodies (mAb) 
The abbreviations used are: GP, glycoprotein; BSA,  bovine serum 
albumin; DAG, diacylglycerol; EGTA, [ethylenebis(oxyethylene- 
nitri1o)ltetraacetic acid; lyso-PA, lysophosphatidic acid;  mAb, mono- 
clonal antibody(ies); PA, phosphatidic acid; PC, phosphatidylcholine; 
PI, phosphatidylinositol; PIP, phosphatidylinositol 4-phosphate; 
PIP2, phosphatidylinositol 4,5-bisphosphate; PS, phosphatidylserine; 
PGI,, prostacyclin; PMA, phorbol 12-myristate 13-acetate; Hepes, 4- 
(2-hydroxyethyl)-l-piperazineethanesulfonic acid. 
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(O'Toole et al., 1991) and RGD-containing peptides (Du et 
al., 1991) can induce high levels of fibrinogen binding to 
recombinant and purified GP IIb-IIIa. To date, receptor- 
mediated activation of the fibrinogen binding properties of 
GP IIb-IIIa has been observed only in intact  and saponin- 
permeabilized platelets (Shattil  and Brass, 1987). 
Platelet agonists, including thrombin, ADP, and thrombox- 
ane Az, which increase the fibrinogen binding properties of 
platelets, elicit polyphosphoinositide hydrolysis and/or Ca2+ 
mobilization (Rittenhouse-Simmons, 1979; Leung et al., 1983; 
Seiss et al., 1985) and therefore are thought to release the two 
second messengers diacyglycerol (DAG) and inositol trisphos- 
phate. Although treatment of permeabilized platelets with 
either phorbol esters or Ca2+ ionophores converts GP IIb-IIIa 
to a functional fibrinogen receptor (Shattil  and Brass, 1987), 
neither direct phosphorylation of GP  IIb-IIIa (Hillery et al., 
1991) nor changes in intracellular Ca2+ levels (Shattil and 
Brass, 1987) appear to be the final mediator of GP  IIb-IIIa 
activation. Platelet activation is accompanied by stimulation 
of phosphatidylinositol (PI)-specific phospholipase C, phos- 
phatidylcholine (PC)-specific phospholipases C and D, and 
arachidonate-releasing phospholipase Az. In addition to  their 
water-soluble products, the action of these enzymes results  in 
generation of  DAG, phosphatidic acid (PA),  and lysophospho- 
lipids. Additionally, production of D-3 phosphate-containing 
inositol lipids is stimulated in agonist-treatedplatelets (Nolan 
and Lapetina, 1990; Kucera and Rittenhouse, 1990). 
Three lines of evidence suggest that lipids may be important 
in modulating the ligand binding function of integrins. The 
avidity of members of the p2 family of integrins, including 
and a&, is enhanced by a lipid factor  (termed integrin- 
modulating factor-1) extracted from activated polymorpho- 
nuclear leukocytes (Hermanowski-Vosatka et al., 1992). In- 
tegrin-modulating  factor-1  enhances the ligand binding prop- 
erties of a& and a& in  intact cells and purified a&. In 
addition, the binding specificity and affinity of isolated vitro- 
nectin receptor (aVp3), which shares the same @-chain as  GP 
IIb-IIIa but  has a different a-chain, is altered by insertion 
into liposomes of different compositions (Conforti et al., 
1990). Finally, in human melanoma cells avp3 exists in a 
calcium-dependent complex with the disialoganglioside GD2, 
and  the addition of GD2 to purified a,P3 enhances its binding 
to RGD-containing peptides (Cheresh et al., 1987). In this 
study, we examined the ability of lipids to enhance fibrinogen 
binding  to purified GP IIb-IIIa. We have found that fraction- 
ated lipids from agonist-treated  platelets as well as purified 
PA and lyso-PA can increase fibrinogen binding to mAb- 
immobilized GP IIb-IIIa. 
EXPERIMENTAL  PROCEDURES 
Materials-Glycerophosphates and monoacylglycerol  were pur- 
chased from  Sigma. Phosphatidylinositol 4-phosphate (PIP) and 
phosphatidylinositol 4,5-bisphosphate (PIPz) were purified from rat 
brain Folch fraction I and supplied by Dr. Andrew Morris, University 
of North Carolina. Bovine brain phosphatidylserine (PS), egg PC, 
egg  PA, l-oleoyl,2-hydroxyglycero-3-phosphate and 1,2-dicaproyl-sn- 
glycero-3-phosphate were purchased from Avanti Polar Lipids, Ala- 
baster, AL. 
Antibodies-The GP IIIa-specific mAb AP3 (Newman et al.,  1985) 
was kindly supplied by Dr. Peter Newman, the Blood Center of 
Southeastern Wisconsin; the  GP IIb-specific mAb Tab (McEver et 
al., 1980) was the generous gift of Dr. Rodger McEver, Oklahoma 
Medical Research Foundation. Although their  determinants  are ex- 
tracellular, neither AP3 nor Tab interferes with fibrinogen binding 
to GP IIb-IIIa on activated platelets. The GP IIb-IIIa complex- 
specific mAb 10E5, which inhibits platelet aggregation and fibrinogen 
binding (Coller et al., 1983), was generously supplied by Dr. Barry 
Coller, SUNY-Stony Brook. The anti-fibrinogen mAb 1D4, which 
cross-reacts with amino acids 241-476 on the A a  chain, and mAb 
Shainoff, which cross-reacts with amino acids 15-21 on the BO chain, 
were obtained from Dr. B. Kudryk, New York  Blood Center. 
Platelet Isolation and Lipid Extraction-Fresh human platelets 
were obtained from acid citrate dextrose-anticoagulated venous blood 
of adult donors by the procedure of Mustard et al.  (1989) and washed 
twice with Caz+- and Me-f ree  Tyrode's buffer (138 mM NaCl, 12 
mM NaHC03, 10 mM KCl, 5.5 mM glucose, 0.36 mM Na,HPOr, 10 
mM Hepes, pH 7.4) containing 150 nM prostacylin (PGI,) and 0.35% 
bovine serum albumin (BSA). The platelets were resuspended in 
Ca2+- and Me-f ree  Tyrode's buffer (0.5-1 X lo9 platelets/ml) at 
37 "C and treated with 0.2-0.5 unit/ml thrombin for 30 s, 0.68 p~ 
U46619 for 1 min, 5 p M  phorbol 12-myristate 13-acetate  (PMA) for 
5 min, or 150 nM PGIz for 1 min. For steady-state 32P labeling of 
phospholipids, the platelets were incubated with 32Pi for 4 h, as 
described previously (Hillery et al., 1991), before exposure to agonists. 
Lipids were extracted as described by Allan and Michell (1978), dried 
under Nz, and resuspended in 1 ml  of  CHCl,. 
For separation by anion exchange chromatography, platelet lipid 
extracts were applied to a  1-ml DEAE-cellulose column (Whatman) 
that was prepared by the procedure of Low (1990) and equilibrated 
in CHC13. The column was washed sequentially with 10 column 
volumes of CHC13, 9 volumes of 9 1  CHC13:MeOH (v/v),  9 volumes 
of 7:3 CHC13:MeOH (v/v),  9 volumes of 1:l CHCkMeOH (v/v), 10 
volumes of 20:9:1 CHC13:MeOH:H20 (v/v), and 10 volumes each of 
20:9:1  CHC13:MeOH:Hz0 (v/v/v) with 100,  200, and 500 mM ammo- 
nium acetate. Each fraction was reextracted as described above and 
the CHC13 phase stored at -20 'C until further use. To separate 
polyphosphoinositides, the whole lipid extract was applied to neo- 
mycin-linked glass beads (0.5-ml bed volume) and eluted as described 
(Morris et al., 1990). Thin layer chromatography (TLC) was per- 
formed as described by Ferrell and Huestis (1984) with the first 
dimension in 6030:6 CHC13:MeOHNH40H (v/v/v) followed  by 
60:10:6 CHCl3:MeOH:CH3COOH (v/v/v). Phospholipids were stained 
with Iz; radiolabeled phospholipids were detected by autoradiography. 
Phospholipid phosphorus was quantitated with Malachite Green by 
the method of Itaya and Ui (1966). 
Protein Purification and Iodination-Fibrinogen was purified from 
fresh-frozen plasma by the glycine precipitation method of Kazal et 
al. (1963). Contaminating fibronectin was  removed by gelatin-Seph- 
arose chromatography. The concentration of fibrinogen was deter- 
mined spectrophotometrically at 280 nm, assuming an extinction 
coefficient (0.1%) of 1.51 and a molecular mass of 340,000 daltons. 
Fibrinogen was centrifuged (11,600 X g) for 5 min before  use. Fibrin- 
ogen  (300  pg) or antibody (100  pg)  was radioiodinated by incubation 
with 1 mCi  of NalZsI (Amersham Corp.) and 0.05 mg/ml chloramine 
T for 5 min at room temperature. The reaction was stopped with 0.05 
mg/ml sodium metabisulfite, and unincorporated NalZSI was  removed 
by  gel filtration on a  Pharmacia  PD-10 ((3-25 M) column (Pharmacia 
LKB Biotechnology Inc.). The specific activity of 12SI-labeled protein 
was > 1 X 10" cpm/mol. Chloramine T-catalyzed iodination does not 
alter  the ability of fibrinogen to bind to activated platelets (Marguerie 
et al., 1979). 
Glycoprotein IIb-IIIa was purified from washed, outdated platelets 
lysed in 1% Triton X-100,0.15 M NaCl, 1 mM CaCl,,  20 mM Tris,  pH 
7.4, 50 p M  leupeptin, 0.1 mM phenylmethylsulfonyl fluoride, and 1 
pg/ml aprotonin by modification of the procedure of Fitzgerald et al. 
(1985). Glycoproteins were isolated at room temperature by concan- 
avalin A affinity chromatography in 0.1% Triton X-100,0.15 M NaC1, 
1 mM CaCl,,  20 mM Tris, pH 7.4. The concanavalin A-retained 
glycoproteins were eluted with the same buffer containing 300 mM a- 
methyl D-mannose and applied to sequential heparin-Sepharose, gel- 
atin-Sepharose, and Sephacryl s-300 columns. The concentration of 
GP IIb-IIIa was determined by the Pierce BCA protein assay (Pierce 
Chemical Co.) with BSA as the  standard. A molecular mass of  265,000 
daltons for the  GP IIb-IIIa complex  was assumed. 
Fibrinogen Binding to Purified, mAb-immobilized G P  IIb-IIIa- 
Microtiter wells (Immulon 2 Removawell strips, Dynatech Labs, 
Chantilly, VA)  were incubated with 50 pl of the  GP IIIa-specific mAb 
AP3 (15 pg/ml) in buffer A (100 mM NaCl, 0.05% NaN3, 50 mM Tris, 
pH 7.4) overnight at 4 "C. In some experiments, the  GP IIb-specific 
mAb Tab served as the capturing antibody. To lower nonspecific 
binding, the wells  were  blocked in buffer A containing 0.5% BSA for 
1 h at 4 "C. After washing, the wells were incubated for 6-18 h at 
4 "C with 50 pl of purified GP IIb-IIIa (20 pglml) in buffer A 
containing 0.035% Triton X-100 and 1 mM CaClZ. Uncaptured GP 
IIb-IIIa was  removed  by washing the wells with buffer A containing 
1 mM CaClZ. Binding reactions were conducted in a  total volume of 
100 pl containing lZ5I-labeled ligand, 100 mM NaCl, 1 mM CaCI,, 50 
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mM Tris, pH 7.4, and 0.5% BSA. To test  the effects of lipids on the 
fibrinogen binding activity of GP IIb-IIIa, lipids were dried, resus- 
pended in buffer A, sonicated for 5 min in a water bath sonicator 
(Laboratory Supplies Inc., Piscataway, NJ),  and added to  the binding 
reaction. Unless otherwise indicated, the binding reactions proceeded 
for 1 h at room temperature, at which time the wells were washed 
three times with 300 pl of buffer A containing 1 mM CaC12, and  the 
amount of radioactivity associated with the well was quantitated. 
Nonspecific binding was defined by performing the assay either  in 
microtiter wells that were coated with BSA instead of AP3 or in AP3- 
coated wells that had been incubated with buffer A containing Triton 
X-100 but lacking GP IIb-IIIa. 
Enzymatic Degradation of PA-PA was dried, resuspended in Tris/ 
NaCl buffer  (100 mM NaC1,50 mM Tris,  pH 7.4) to 400 p M  or 4 mM, 
and incubated with 0.01-10 units/ml of alkaline phosphatase (Boeh- 
ringer Mannheim), snake venom phospholipase AB, or Vibrio phos- 
pholipase B (Sigma) for 1 h at 37 "C. For alkaline phosphatase 
reactions, PA was resuspended in buffer a t  pH 8.0, and  the buffer 
was readjusted to pH 7.4 after the incubation. In some instances, the 
reactions were reextracted, separated by two-dimensional TLC,  and 
visualized by staining with I p  or by detecting phospholipid phosphorus 
with the reagent of Dittmer and Lester (1964). 
Production of p2P]Lyso-PA and Binding of r2P]Lyso-PA to mAb- 
immobilized G P  IIb-IIIa-[32P]Lyso-PA was generated by DAG ki- 
nase-catalyzed phosphorylation of monoacylglycerol in the presence 
of [32P-y]ATP (Du Pont-New  England Nuclear; specific activity 2.2 
X 10" cpm/mol) essentially as described (Preiss  et al., 1986), except 
that membranes were replaced with monoacylglycerol. After a 3-h 
incubation at 37 "C, lipids were extracted  as described above. ["PI 
Lyso-PA binding to mAb-immobilized GP IIb-IIIa was performed 
under the same conditions as fibrinogen binding. Nonspecific binding 
was determined by measuring the binding of [32P]lyso-PA to wells 
lacking GP IIb-IIIa. 
Fibrinogen Binding to G P  IIb-IIIa Incorporated into Phospholipid 
Vesicles-GP IIb-IIIa was exchanged into  the dialyzable detergent 
octyl glucoside and incorporated into phospholipidvesicles containing 
PS:PC (2:l molar ratio) or PS:PC:PA (2:1:0.4 molar ratio) as de- 
scribed by Parise and Phillips (1985b). Fibrinogen binding to  GP IIb- 
IIIa incorporated in phospholipid vesicles  was determined by incu- 
bating the vesicles in 0.1 M NaC1, 1 mM CaCl,, 0.5% BSA, 0.02% 
NaN3, 50 mM Tris,  pH 7.4, in the presence of lB5I-fibrinogen for 1 h 
at room temperature. Saturability and specificity of the reactions 
were demonstrated by including 1.5 p~ nonradioactive fibrinogen in 
the reaction. Nonspecific binding was determined by incubating phos- 
pholipid vesicles lacking GP IIb-IIIa with IB5I-fibrinogen. The reac- 
tions were terminated by filtration, the filters were washed three 
times with 1 ml of ice-cold buffer (0.1 M NaC1, 1 mM CaClB, 0.02% 
NaN3, 50 mM Tris, pH 7.4), and  the radioactivity associated with the 
filters was quantitated. Parallel reactions, in which IB5I-mAb 10E5 
replaced '251-fibrinogen,  were conducted to quantitate the amount of 
GP IIb-IIIa available for binding. 
Fibrinogen Binding to Purified Platelet Membranes-Washed 
platelets were resuspended in 150 mM NaC1, 10 mM Tris, pH 7.4, 
placed in the pressure chamber of a Parr cell disruption bomb (Parr 
Instrument Co., Moline, IL), equilibrated with Nz (1200  p.s.i.) for 30 
min,  and discharged into the same buffer with a final concentration 
of  0.1 mM phenylmethylsulfonyl fluroide, 10 pg/ml aprotinin, and 0.1 
mg/ml leupeptin. The suspension was centrifuged (100,000 X g) for 
30 min at 4 'C, and platelet membranes were isolated by sucrose 
density sedimentation as described (Phillips and Baughan, 1983). 
The membranes were treated with various concentrations of phos- 
pholipase D (Sigma) for 30 min at  37 "C. The ability of phospholipase 
D to transfer the phosphatidyl moiety of PC to certain nucleophiles 
such  as  ethanol was  used to quantitate the hydrolysis of PC (Dowson, 
1967;  Meulen and Haslam, 1990). Phospholipase D-catalyzed forma- 
tion of phosphatidylethanol was measured by including 300 mM ["C] 
ethanol  (ICN Biomedicals, Costa Mesa, CA) in some reactions, ex- 
tracting lipids, and quantitating incorporation of the 14C label into 
the lipid fraction. Total phospholipid phosphorus in the membranes 
was quantitated with Malachite Green as described above and aver- 
aged 1,350 nmol of phosphate/mg of protein. PC was assumed to 
represent 40% of total lipid phosphorus (Holmsen, 1990). The pro- 
duction of PA by phospholipase D was verified by extracting lipids 
from platelet membranes that had been treated with buffer or 1 unit/ 
ml of phospholipase D, separating the lipids by two-dimensional TLC, 
and visualizing phospholipids with the reagent of Dittmer and Lester 
(1964). Fibrinogen binding to the membranes was performed as 
described for fibrinogen binding to phospholipid vesicles. The reac- 
tions were terminated by filtration. Nonspecific binding was deter- 
mined by including 1.5 p~ nonradiolabeled fibrinogen in the reac- 
tions. 
Calculations-In each experiment, all assays were performed in 
triplicate. Data are plotted as mean f S.E. Unless otherwise indicated, 
graphs represent the results from three experiments. 
RESULTS 
Fibrinogen Binding Properties of Ab-immobilized G P  ZIb- 
IIIa-The goal of these studies was to determine whether 
lipids can modulate the fibrinogen binding activity of purified 
GP IIb-IIIa. To address this question, we used a microtiter 
plate assay in which GP IIb-IIIa was immobilized by the  GP 
IIIa-specific mAb AP3. The amount of GP IIb-IIIa  captured 
by the mAb AP3 was between 0.32 and 0.45 pmol/well, as 
quantitated by measuring the binding of the GP IIb-IIIa 
complex-specific mAb  10E5. These values correlated well with 
the values obtained for Iz5I-GP  IIb-IIIa binding to the mAb 
AP3-coated wells  (0.33 pmol/well). When  incubated with I T -  
fibrinogen in three experiments, only 15.3 & 3.6%  of the  GP 
IIb-IIIa was capable of binding fibrinogen. Du and co-workers 
(1991) obtained  similar  results with GP IIb-IIIa from deter- 
gent lysates of fresh platelets. Thus,  as observed by others 
using a variety of systems  (Phillips and Baughan, 1983; Parise 
and Phillips, 1985b), the majority of purified GP IIb-IIIa does 
not retain  the fibrinogen binding properties of activated  plate- 
lets. 
Effects of Lipid Extracts from Resting and Activated Platelets 
on Fibrinogen Binding to Purified G P  IIb-IIIa-Lipids were 
extracted from washed platelets treated with platelet  activa- 
tors (thrombin, the thromboxane Ap-mimetic U46619, or 
PMA) or a  platelet  activation-inhibitor (PG12) and tested for 
their effects on fibrinogen binding to  GP IIb-IIIa either before 
or after fractionation of the extracts by anion exchange chro- 
matography. Although Iz5I-fibrinogen binding was not en- 
hanced by the addition of unfractionated lipid extracts to  the 
assay (25 nmol of phospholipid phosphorus/well), the binding 
was increased %fold  by a  fraction  obtained following DEAE- 
cellulose chromatography of lipid extracts from thrombin- 
(Fig. lA) but not PGL-treated platelets (Fig. 1B).  The peak 
of this activity eluted from the column in solvent containing 
100 mM ammonium acetate (fraction 7). A factor with a 
similiar anion exchange chromatography profile but less ac- 
tivity was produced within 10 s of platelet exposure to  throm- 
bin (data not shown). DEAE-chromatography also resolved 
an activity from lipid extracts of U46619- and PMA-treated 
platelets, which increased the lZ51-fibrinogen binding by 3- 
and 3.5-fold, respectively (data not shown). Several fractions 
(e.g. fractions 1 and 2, Fig. 1) appeared to lower fibrinogen 
binding. This effect was probably nonspecific since these 
fractions lowered fibrinogen binding to wells lacking GP IIb- 
IIIa  as well as  to wells containing GP IIb-IIIa. 
The activity in the peak fraction from thrombin-stimulated 
platelets contained a critical monoester phosphate, as evi- 
denced by the ability of alkaline phosphatase treatment (1 
unit/ml) to reduce the fibrinogen binding activity by 58%. 
The inability of alkaline  phosphatase to abolish the activity 
may  be caused by substrate inaccessibility and/or  the presence 
of additional active factors without free phosphate groups. 
Phosphate-containing lipids in  the active DEAE column frac- 
tions were identified by prelabeling platelets to steady-state 
with 32Pi. Thin layer chromatography of fractions 6-9 revealed 
that a 32P-labeled lipid comigrating with authentic PA was 
substantially increased in fraction 7 from thrombin-stimu- 
lated platelets, whereas 32P-labeled lipids comigrating with 
PS and PI  were present in equal amounts  in  fractions from 
either  thrombin-  or  PGIz-treated platelets (Fig. 2). Alkaline 
Lipids  Modulate Fibrinogen Binding to GP IIb-IIIa 15571 
A 










C T L 1 2 3 4 5 6 7 8 9  
Fractions 
FIG. 1. Effect  of DEAE column fractions on 121-fibrinogen 
binding to mAb-immobilized GP IIb-IIIa. Lipids were extracted 
from platelets, which had been treated with either A, 0.5 unit/ml 
thrombin for 30 s or B, 150 nM PGI2 for 1 min at  37  "C, and passed 
over DEAE-cellulose columns as described under  "Experimental Pro- 
cedures." The columns were washed with fraction 1 ,  CHCl3; fraction 
2, CHC13:MeOH 9:l; fraction 3, CHC13:MeOH  7:3; fraction 4, 
CHC13:MeOH 1:l; fractions 5 and 6, CHC13:MeOH:H20 20:9:1; frac- 
tion 7, 100 mM ammonium acetate  in CHC13:MeOH:H20; fraction 8, 
200 mM ammonium acetate  in CHC13:MeOH:H20; and fraction 9,500 
mM ammonium acetate in CHC13:MeOH:H20. Each fraction was 
dried, resuspended in 0.5 ml of buffer A, sonicated, and assayed for 
effects on the binding of  25 nM '*'I-fibrinogen to immobilized GP IIb- 
IIIa. Control (CTL) is the amount of '2'I-fibrinogen bound in the 
absence of added lipids. The  data represent specific binding and  are 
combined results from two experiments. Nonspecific binding was 
defined as  the amount of '251-fibrinogen bound to wells lacking GP 
IIb-IIIa  in the presence of the fractions. Similar  results were obtained 
with lipids extracted from platelets treated with the thromboxane AP- 
mimetic U46619 or PMA. 
phosphatase treatment (1 unit/ml) of fraction 7 from throm- 
bin-stimulated platelets decreased the radioactivity associated 
with the  TLC spot corresponding to PA by 38%  (110,800  dpm 
without enzyme treatment versus 67,500  dpm with treatment). 
When a standard of authenthic PA was separated on the 
DEAE column,  65% of the lipid was recovered in fraction 7 
and 35%  in fraction 8. Thus, PA is one anionic lipid with a 
monoester phosphate that increases with platelet activation 
and is found in the active DEAE  column fraction. 
A second class of anionic lipids with monoester phosphates 
that undergo substantial changes with platelet activation is 
polyphosphoinositides. Although 32P-labeled lipids comigrat- 
ing with authentic PIP and PIP2 were present in DEAE 
column fraction 8, the activity was not retained by neomycin- 
linked glass  beads under appropriate conditions for polyphos- 
phoinositide adsorption to this matrix (data not shown). 
Moreover, neither purified PIP nor PIP2 in concentrations 
from 1 p M  to 1 mM increased fibrinogen binding to purified 
GP IIb-IIIa (Table I). 
Characterization of the Effects of Purified PA on Fibrinogen 
Binding to Purified GP IIb-IIIa-Since the evidence pre- 




FIG. 2. TLC analysis of 32P-labeled lipids in the active 
DEAE column fraction (fraction 7). To identify phosphate-con- 
taining components in fraction 7 from the DEAE column, platelets 
were incubated with n2Pi before exposure to A, thrombin; or R, PGIp. 
Lipids were extracted and fractionated by DEAE chromatography as 
described in the legend to Fig. 1. The lipids in fraction 7 were further 
resolved by TLC  and visualized by autoradiography. The positions of 
lipid standards  (PS,  PI, PA) detected by Ip  are indicated. 1-D and 2- 
D,  first- and second-dimension, respectively. 
TABLE I 
Effects of phospholipids, diacylglycerol, and glycerophosphates on the 
fibrinogen binding activity of GP  Ilb-IIIa 
All compounds were prepared  in 400 p M  stock solutions, pH 7.4. 
Final concentrations in the binding assay were 100 pM. Binding 
reactions were conducted for 1 h at  room temperature  in the presence 
of 50 nM '*'I-fibrinogen. The results are expressed as  the percent of 
sDecific fibrinogen binding. induced by 100 WM PA. 





100 & 5.4 
PC 
23.1 f 7.7 
PIP 
21.1 f 5.5 
28.5 & 15.4 
PIP2 
DAG 
23.1 * 3.8 
16.2 & 7.3 
a-Glycerophosphate 31.1 f 3.0 
&Glycerophosphate 15.2 & 4.6 
No lipid 36.9 f 5.3 
DEAE column fraction, we examined the effects of purified 
PA on fibrinogen binding to  GP IIb-IIIa. PA increased the 
binding of 12'I-fibrinogen to mAb-immobilized GP IIb-IIIa in 
a concentration-dependent manner, with a maximal  effect at 
1 mM (Fig. 3). The results were not  a nonspecific effect of 
lipids in general as other lipids, including PS and PC, did not 
possess similar activity (Table  I). Examination of the radio- 
activity bound to  GP IIb-IIIa in the presence and absence of 
PA by  polyacrylamide gel electrophoresis and autoradiogra- 
phy demonstrated that the "'1 label was associated with the 
Aa, BP, and y chains of fibrinogen.  Moreover, the lipids  did 
not alter the mobility of GP IIb or GP IIIa separated by 
polyacrylamide gel electrophoresis, suggesting that PA does 
not alter the covalent structure of the proteins (data not 
shown). 
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FIG. 3. Concentration dependence of PA-induced "'I-fi- 
brinogen binding  to  mAb-immobilized GP IIb-IIIa. Binding of 
50 nM '251-fibrinogen to wells containing GP IIb-IIIa captured by 
mAb AP3 was determined in the presence of various concentrations 
of PA as described under "Experimental Procedures." The amount of 
GP IIb-IIIa present was quantitated by measuring the binding of  200 
nM '2'I-mAb 10E5. Y-rnAb 10E5 binding was observed only when 
GP IIb-IIIa was added to mAb AP3-coated plates, was inhibited by 
Ca2+ chelators, and was saturable. Varying the concentrations of  PA 
did not alter the levels of lZ5I-mAb 10E5 bound. The  data are ex- 
pressed as mol  of fibrinogen bound/mol of GP IIb-IIIa, and specific 
binding is  shown. When GP IIb-IIIa was captured with the  GP IIb- 
specific mAb Tab similar results were obtained. 
Three lines of evidence indicate that PA did not  increase 
fibrinogen binding nonselectively, but promoted a specific 
interaction between GP IIb-IIIa and fibrinogen. First, the 
effects of PA depended on the presence of GP IIb-IIIa, and 
P A  did not  alter the  amount of GP IIb-IIIa  captured by mAb 
AP3  (data not  shown). Second, when wells  were coated with 
the anti-fibrinogen mAb Shainoff or 1D4, PA did not  alter 
the levels of fibrinogen bound to these mAb  (Fig. 4), suggest- 
ing that PA was not increasing the amount of fibrinogen 
bound to GP IIb-IIIa by inducing molecular interactions 
between fibrinogen molecules; if PA were nonspecifically pro- 
moting fibrinogen binding, its effect should be independent 
of the protein to which fibrinogen is binding. Third,  the PA- 
induced fibrinogen binding was inhibited by agents known to 
inhibit fibrinogen binding to  GP IIb-IIIa, including nonra- 
dioactive fibrinogen, divalent cation  chelation, mAb 10E5, the 
peptides GRGDS and H12, but not the control peptide 
GRGESP (Fig. 5). Thus, PA-stimulated fibrinogen binding to 
mAb-immobilized GP IIb-IIIa possesses many of the proper- 
ties of fibrinogen binding to the GP IIb-IIIa complex on 
activated  platelets. However, PA increased fibrinogen binding 
to Ab-immobilized GP IIb-IIIa  containing the subunit 
with properties similar to those described above (data not 
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FIG. 4. PA does not alter '2'I-fibrinogen binding to anti- 
fibrinogen mAb. Microtiter wells  were coated with 50 pl of the  anti- 
fibrinogen mAb ID4 or Shainoff (0.015 mg/ml) or BSA (0.015 mg/ 
ml). "'I-Fibrinogen (15 nM) was incubated with the wells for 1 h at 
room temperature without (open bars) or with (solid bars) the addition 
of 1 mM PA. The wells  were washed three times, and  the radioactivity 
associated with the well  was quantitated. lZ5I-Fibrinogen binding in 
the presence or absence of P A  was inhibited by the inclusion of 1.5 
p~ fibrinogen ( F G )  in the assay (hatched bars). Data  are graphed as 
Dmol of total 'Z51-fibrinosen bound. Results from one experiment 
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FIG. 5. Inhibition  of  PA-induced  '"1-fibrinogen  binding  by 
agents that inhibit platelet aggregation. Immobilized GP IIb- 
IIIa was incubated with 50 nM '"I-fibrinogen and 1 mM PA. The 
specificity of PA-induced binding was verified by including 0.5 mM 
GRGDS peptide, 0.5 mM GRGESP peptide, 0.5 mM H12 peptide, 1.5 
WM mAb 10E5, 5 mM EGTA, or  1.5 p~ fibrinogen (FG)  in the assay 
as indicated. Basal levels of binding of lZ5I-fibrinogen to immobilized 
GP IIb-IIIa, measured in the absence of PA and inhibitors, is indi- 
cated ( N o  P A ) .  Data are graphed as pmol of 'T-fibrinogen specifically 
bound; nonspecific binding was defined by incubating wells lacking 
GP IIb-IIIa with lZ5I-fibrinogen and  the indicated agents. 
substitution of  Asp"' by Tyr in GP IIIa, does not  bind RGD 
peptides and cannot be activated to bind fibrinogen when 
expressed on intact cells (Loftus  et al., 1990). 
Determination of Kinetic and Equilibrium Binding Con- 
stants-Binding of lZ5I-fibrinogen (30 nM) in the presence of 
25 PM, 100 PM, or 1 mM PA reached steady state within 
approximately 60 min at  room temperature (Fig. 6). The 
association rate  constant ( k l )  for fibrinogen binding mediated 
by PA was  4.5 X lo5 M-' min-l. Altering the concentration of 
PA in the assay did not affect the kl. Nonradioactive fibrin- 
ogen (1.5 PM) added at 60 min dissociated 77% of the radio- 
labeled fibrinogen within 30 min. Dissociation over the first 
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FIG. 6. Time course and reversal of 12"I-fibrinogen binding 
to mAb-immobilized GP IIb-IIIa in the presence of PA. Micro- 
titer wells containing GP IIb-IIIa were incubated with 30 nM "'I- 
fibrinogen for the indicated times (solid  symbols) in the presence of 
25 WM (diamonds), 100 FM (triangles), or 1 mM PA (circles). Nonra- 
dioactive fibrinogen was added after 60 min (arrow) to displace bound 
"'I-fibrinogen (open symbols). Data  are  plotted as percent maximal 
binding, defined as the amount of "'I-fibrinogen specifically bound 
in  the presence of 1 mM PA after 1 h at room temperature. 
10 min in the presence of 100 p~ and 1 mM PA occurred with 
an average rate constant ( k z )  of 4.42 x min". A kinetic- 
ally derived dissociation constant (& = k2 /k l )  of 100 nM was 
obtained. 
Equilibrium binding studies revealed that fibrinogen bind- 
ing in the presence of 100 pM or 1 mM PA was saturable (Fig. 
7). A Scatchard transformation of the saturation binding 
isotherms (Fig. 7 B )  indicated that  the lZ5I-fibrinogen binding 
promoted by PA occurs apparently to a single class of sites, 
presumably GP IIb-IIIa. Dissociation constants for fibrinogen 
binding  in the presence of 100 p~ and 1 mM PA were 50 and 
62 nM, respectively, in agreement with the kinetically derived 
KD. The  apparent maximal binding capacity of GP IIb-IIIa 
was 0.42 mol  of fibrinogen/mol of GP  IIb-IIIa in the presence 
of 100 p~ PA and 1.1 mol of fibrinogen/mol of GP IIb-IIIa  in 
the presence of 1 mM PA. The binding isotherm  obtained in 
the absence of PA was not analyzed by the method of Scat- 
chard since the  amount of '251-fibrinogen bound did not in- 
crease appreciably with increasing concentrations of 1251-fi- 
brinogen. Our results suggest that PA increases the proportion 
of fibrinogen-binding competent GP  IIb-IIIa complexes and 
has little or no effect on the affinity of GP IIb-IIIa for 
fibrinogen. 
Structural Requirements of PA Actiuity-The structural 
requirements for PA activity were evaluated by testing  the 
effects of enzymatically treated PA and derivatives of PA on 
fibrinogen binding to  GP IIb-IIIa.  Preincubation of PA with 
alkaline  phosphatase or phospholipase B for 1 h at  37 "C dose- 
dependently decreased the ability of PA to induce fibrinogen 
binding to  GP IIb-IIIa (Fig. 8, A and B ) .  These observations 
were supported by the finding that neither purified DAG, a 
product of alkaline phosphatase, nor a-glycerophosphate, a 
product of phospholipase B, was capable of inducing fibrino- 
gen binding to  GP IIb-IIIa  (Table I). /3-Glycerophosphate was 
also without effect (Table I). Preincubation of a maximal 
concentration of PA (1 mM) with up to 1 unit/ml phospholi- 
pase A2 had no effect on the ability of PA to induce fibrinogen 
binding (Fig. 8C, solid line). Under these  conditions, resolu- 
tion of the products by TLC revealed that phospholipase A2 
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FIG. 7. Saturation binding isotherm and Scatchard analysis 
of ""I-fibrinogen binding to mAb-immobilized GP IIb-IIIa in 
the presence of PA. A, microtiter wells containing GP IIb-IIIa were 
incubated with no added (open circles), 100 PM (closed triangles), or 
1 mM (closed circles) PA and concentrations of lZ5I-fibrinogen as 
indicated. Data are plotted as pmol of '251-fibrinogen specifically 
bound and B, replotted as pmol specifically bound uersus bound 
ligand divided by free ligand according to  the method of Scatchard 
(1949). The dissociation constants (KD) were 50 and 62 nM in the 
presence of 100 pM and 1 mM PA, respectively. The  amount of GP  
IIb-IIIa captured by mAb AP3 was quantitated by measuring the 
binding of  "'I-mAb 10E5. Maximal binding capacities of  0.42 and 1.1 
mol of fibrinogen bound/mol of GP IIb-IIIa were obtained, respec- 
tively. 
phospholipase A2  (10-100 units/ml) lowered the activity of 1 
mM PA and reduced the  total amount of PA and lyso-PA in 
the reaction. One interpretation of these results is that  at 
high concentrations, phospholipase A2 generates glycerophos- 
phates which, in turn, inhibit PA-induced fibrinogen binding 
(see below). However, preincubation of a submaximal concen- 
tration of PA (100 p ~ )  with phospholipase A2 increased both 
the levels of lyso-PA in  the reaction and  the ability to promote 
fibrinogen binding (Fig. 8C, dashed line). 
These  results suggested that lyso-PA is a potent activator 
of fibrinogen binding to  GP IIb-IIIa. Indeed, we found that a 
synthetic lyso-PA (l-oleoyl,2-hydroxyglycero-3-phosphate) 
induced fibrinogen binding to  GP 1%-IIIa in  a dose-dependent 
manner, with an EC50  of 50 FM (Fig. 9,  solid l ine),  which  was 
slightly more potent  than commercially obtained PA, which 
had an ECS0 of 100 p ~ .  It should be noted that  at concentra- 
tions > 1 mM, the synthetic lyso-PA increased fibrinogen 
binding to  the microtiter wells in  the absence of GP IIb-IIIa. 
The critical micellar concentration of lyso-PA is reported to 
be 1.3 mM at  pH 7.4 (Jalink  et al., 1990), and  this increase in 
nonspecific binding may represent  interactions of fibrinogen 
with lyso-PA micelles. 
Examination of the purified PA by TLC revealed that no 
detectable lipid chromatographed with lyso-PA, and approx- 
imately 10% or less of the lipid chromatographed with PC. 
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FIG. 8. Enzymatic alterations in the ability of PA to induce 9-fibrinogen binding  to mAb-immobilized GP IIb-IIIa. PA, 
resuspended and sonicated in  Tris/NaCl buffer, was preincubated with various concentrations of A, alkaline phosphatase; B,  phospholipase 
B; or C ,  phospholipase A, as described under  “Experimental Procedures” before addition to binding reactions containing 50 nM 1251-fibrinogen. 
Final concentrations of P A  in the binding assays were  100 U M  (dashed lines) or 1 mM (solid  lines). Data  are graphed as a percent of specific 
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FIG. 9. Concentration-dependent induction of ”‘1-fibrino- 
Ben binding to mAb-immobilized GP IIb-IIIa by P A  analogs. 
Microtiter wells containing immobilized GP IIb-IIIa were incubated 
with various concentrations of a synthetic lyso-PA (l-oleoyl,2-hy- 
droxyglycero-3-phosphate; solid  line) or a synthetic PA (1,2-dica- 
proyl-sn-glycero-3-phosphate; dashed  line) and 50 nM lZ5I-fibrinogen 
for 1 h  as described under “Experimental Procedures.” The  data are 
graphed as percent maximal binding induced by 1 mM PA. 
Although we cannot rule out  the possibility that  the effects 
ascribed to PA are caused by  low levels of contaminating lyso- 
PA,  this is unlikely since the dose-response curves suggest 
that  at least 10% of the lipid in the PA would have to be lyso- 
P A  to produce the observed effects. 
Although these  results may provide insight into  the  struc- 
tural requirements for P A  activity and potential mechanisms 
of P A  interaction with GP IIb-IIIa, it is possible that the 
effects of PA are caused by the macromolecular form assumed 
by the lipid in aqueous solution. Therefore, several chemical 
forms of PA that assume different macromolecular structures 
were compared. Synthetic 1,2-dicaproyl-sn-glycerol-3-phos- 
phate, which forms micelles when sonicated in aqueous solu- 
tion, induced fibrinogen binding with an EC50  of 250 PM (Fig. 
9, dashed  line) a slightly higher EC50 than  that of PA, which 
forms bilayers when sonicated in aqueous solution (Cullis et 
al. 1983). Moreover, lyso-PA was active at  concentrations 
below its critical micellar concentration, conditions in which 
lipid monomers are expected to predominate (Fig. 9). Based 
on  these  results, we believe that  it is the chemical structure 
and not the macromolecular structure assumed by PA in 
solution that is more important in determing its ability to 
promote fibrinogen binding. 
Our studies imply that there is an interaction between PA 
or lyso-PA and  GP IIb-IIIa. We therefore examined the ability 
of [32P]lyso-PA to bind directly to  GP IIb-IIIa.  [32P]Lyso-PA 
bound specifically and dose-dependently to  GP IIb-IIIa im- 
mobilized by mAb AP3 (Fig. 1OA). Moreover, [32P]lyso-PA 
binding to  GP IIb-IIIa was inhibited by nonradiolabeled lyso- 
PA, PA, and a-glycerophosphate, but not DAG or P-glycero- 
phosphate (Fig. 10B). The inhibition of binding by a-glycer- 
ophosphate suggested that  this compound might alter PA- 
induced fibrinogen binding. When  tested, a-glycerophosphate 
did inhibit PA-induced fibrinogen binding to mAb-immobi- 
lized GP IIb-IIIa, whereas DAG or monoacylglycerol failed to 
inhibit binding (data not  shown). 
Effect of PA  on   the  Fibrinogen  Binding  Activity  of  GP ZZb- 
ZZZa Reconstituted i n  Phospholipid Vesicles and in Purified 
Platelet Membranes-Having established an effect of PA on 
the fibrinogen binding properties of mAb-immobilized GP 
IIb-IIIa, we examined the effect of PA on fibrinogen binding 
to  GP IIb-IIIa  reconstituted into phospholipid vesicles. The 
glycoprotein was incorporated by detergent dialysis into phos- 
pholipid vesicles composed of PS:PC or PS:PC:PA. AS ex- 
pected based on previous studies  (Parise and Phillips, 1985a), 
different amounts of GP IIb-IIIa were either incorporated 
into  and/or recovered with vesicles of different lipid compo- 
sitions (see Fig. 11, legend). Therefore, the fibrinogen binding 
results are expressed per mol of accessible GP IIb-IIIa as 
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FIG. 10. [32P]Lyso-PA binding to 
mAb-immobilized GP IIb-IIIa. A ,  mi- 
crotiter wells containing GP IIb-IIIa 
were incubated  with various concentra- 
tions of [32P]lyso-PA for 1 h a t  room 
temperature  as described under  “Exper- 
imental Procedures.” B, [32P]lyso-PA (1 
PM) binding was determined in the  ab- 
sence  (indicated as CTL) or the presence 
of nonradiolabeled lyso-PA (100 p ~ ) ,  PA
(100 pM), diacylglycerol(100 pM), or gly- 
cerophosphates (100 p ~ )  as indicated. 
The  data  are expressed as pmol of [32P] 
lyso-PA specifically bound. Nonspecific 
binding was determined by quantitating 
the amount of [3ZP]lyso-PA binding to 
wells lacking GP  IIb-IIIa. 
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c lzsI-fibrinogen  binding to GP IIb-IIIa in- Ifi, 
corporated into phospholipid -vesicles. Phospholipid vesicles 
composed of PS:PC or PS:PC:PA were formed with GP IIb-IIIa  as 
described  under  “Experimental Procedures.” The phospholipid vesi- 
cles were incubated with 50 nM Iz5I-fibrinogen or 200 nM lZ5I-mAb 
10E5 for 1 h at room temperature. Where indicated, 1.5 p~ fibrinogen 
(FG)  was included in the reactions  with Iz5I-fibrinogen (hatched bars). 
Data  are graphed as mol of Iz5I-fibrinogen bound/mol of lZ5I-mAb 
10E5 bound. The  amount of GP IIb-IIIa acessible for ligand binding 
was 2.5-fold  lower in the PS:PC:PA vesicles as determined by meas- 
uring  the binding of lz5I-mAb 10E5. Nonspecific binding was deter- 
mined by measuring the binding of 1251-ligand to phospholipid vesicles 
formed  without GP IIb-IIIa. 
determined by measuring the binding of 1251-10E5. Vesicles 
composed of PS:PC:PA bound 4.2-fold more fibrinogen/mol 
of GP IIb-IIIa than did vesicles formed with PS:PC only (Fig. 
11). Furthermore, ’251-fibrinogen binding to  the vesicles was 
specific and saturable, as evidenced by the ability of nonra- 
dioactive fibrinogen to  inhibit lZ5I-fibrinogen binding. In con- 
trast,  the addition of exogenous PA to  GP  IIb-IIIa incorpo- 
rated in PS:PC vesicles did not alter fibrinogen binding. These 
results suggest that PA in  a membrane environment, either 
by directly interacting with GP IIb-IIIa or by altering the 
vesicle structure,  enhances fibrinogen binding to  GP IIb-IIIa. 
Finally, PA was generated in purified platelet  membranes 
to determine the effects on fibrinogen binding to  the mem- 
branes. Less than 10% of the  GP IIb-IIIa  in the membranes 
B 
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retains the ability to bind fibrinogen; these low levels of 
fibrinogen binding can be increased by certain  manipulations 
of the membranes (Smyth  and Parise, 1992). Incubation of 
platelet membranes with 1-10 units/ml of phospholipase D 
resulted in the hydrolysis of 10-30% of the  PC (control levels, 
-550 nmol of PC/mg of protein).  When  incubated with 30 
nM ‘251-fibrinogen, control membranes bound 5.2 pmol of 
fibrinogen/mg of protein, whereas membranes treated with 1 
and 10 units/ml phospholipase D bound 4.4 and 3.2 pmol of 
fibrinogen/mg of protein, respectively. No change in the 
amount of GP IIb-IIIa, as judged by  ’251-mAb 10E5 binding 
(300 pmol/mg of protein), was observed. Thus, we have not 
been able to demonstrate that elevations of PA can induce 
fibrinogen binding to  GP IIb-IIIa  in isolated platelet mem- 
branes. Although the reasons for a lack of effect in this more 
complicated environment are unknown, the results may have 
interesting implications with regard to  the physiologic mech- 
anism of GP IIb-IIIa activation (see “Discussion”) or may 
indicate that  the PA produced in this manner may not have 
the proper accessibility to GP IIb-IIIa or may disrupt the 
normal membrane structure. 
DISCUSSION 
The preeminence of integrins  in mediating diverse cellular 
adhesive processes, such as platelet aggregation and wound 
healing, is well established. In contrast, relatively little is 
known about the mechanisms by which the ligand binding 
properties of certain integrins are modulated during cellular 
activation. In  an  attempt  to identify factors that may regulate 
the binding function of the major platelet  integrin, GP IIb- 
IIIa, we investigated the effects of lipids on the fibrinogen 
binding properties of purified GP IIb-IIIa. We report that 
fractionated lipids from thrombin-activated  platelets  contain- 
ing PA, as well as purified PA, and lyso-PA can increase 
fibrinogen binding to purified, mAb-immobilized GP IIb-IIIa. 
DEAE chromatograpy of lipid extracts from thrombin-, 
U46619-, or PMA-activated, but not PG12-inhibited platelets, 
resolves a lipid fraction that increases fibrinogen binding to 
mAb-immobilized GP IIb-IIIa. The factor from thrombin- 
stimulated  platelets  appears to have a monoester phosphate 
group that is important for at  least part of its activity (-60%). 
A likely candidate for this activity is PA, since it is the major 
32P-labeled lipid that increases in  the active fractions. The 
possibility that active factors without alkaline  phosphatase- 
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sensitive groups might also contribute to  this activity requires 
further investigation. The sensitivity of our activity to alka- 
line phosphatase distinguishes it from integrin-modulating 
factor-1 isolated by Hermanowski-Vostaka et al. (1992) from 
lipid extracts of activated polymorphonuclear leukocytes. 
Purified PA appears to promote a specific and saturable 
interaction between mAb-immobilized GP IIb-IIIa and solu- 
ble fibrinogen that  has many  properties similar to those of 
fibrinogen binding to  GP IIb-IIIa on the surface of activated 
platelets. Lpecifically, PA-mediated fibrinogen binding to pu- 
rified GP IIb-IIIa is inhibited by calcium chelation, an RGD- 
containing peptide, a peptide corresponding to  the y-chain of 
fibrinogen, and a GP IIb-IIIa complex-specific mAb. Maxi- 
mally effective concentrations of PA induce a 1:l molar ratio 
of fibrinogen binding to  GP IIb-IIIa. The affinity constant 
for fibrinogen binding to  GP IIb-IIIa in  the presence of PA 
(-55 nM) is in  the range of reported values for the affinity 
constant for fibrinogen binding to activated  platelets (50-500 
nM; for review see Plow and Ginsberg, 1989). Analysis of 
fibrinogen binding in the presence of PA indicates that  the 
lipid increases the proportion of fibrinogen-binding compe- 
tent  GP IIb-IIIa complexes with little or no effect on the 
affinity of GP IIb-IIIa for fibrinogen. In one regard, the PA- 
induced fibrinogen binding differed from fibrinogen binding 
to GP IIb-IIIa on intact platelets: namely, PA increased 
fibrinogen binding to  the Cam variant of GP IIb-IIIa, which 
is unable to recognize ligands on platelets. The ability of P A  
to increase fibrinogen binding to  the Cam variant of GP  IIb- 
IIIa suggested that PA may enhance binding by interacting 
with fibrinogen. Although we cannot unequivocably eliminate 
this possibility, we were unable to detect an effect of PA  on 
fibrinogen binding to anti-fibrinogen  antibodies (Fig. 4), sug- 
gesting that if PA is acting on fibrinogen the effect is specific 
for the fibrinogen-GP IIb-IIIa interaction. 
The ability of PA to promote fibrinogen binding to  GP IIb- 
IIIa is not a general property of negatively charged lipids. 
Although the loss of activity of the platelet lipid extract  and 
purified PA with alkaline phosphatase treatment suggests 
that the monoester phosphate is important, the negative 
charge provided by the phosphate or the phosphate per se is 
not sufficient. Other negatively charged lipids (PS,  PI,  the 
monoester phosphate-containing PIP  and  PIP2) or the water- 
soluble analogs of PA (a- and /3-glycerophosphate) were with- 
out effect. Neutral lipids (DAG, PC) were also inactive. At 
least one fatty acid chain is also required for the activity, 
since lyso-PA, but not a-glycerophosphate, is apotent inducer 
of fibrinogen binding to  GP IIb-IIIa. However, fatty acids of 
different  chain lengths in  PA or active analogs are effective 
(Fig. 9). 
The specific chemical structure of the lipid appears to be 
more important  than  the macromolecular forms assumed by 
the active lipids in solution for this activity since lipids 
expected to form monomers, bilayers, or micelles in  solution 
were active. Lyso-PA monomers may account for the  apparent 
increase in potency of lyso-PA relative to PA. This relation- 
ship might not necessarily hold with GP IIb-IIIa  incorporated 
into membranes, in which both lyso-PA and PA would be 
soluble. The monomeric nature of lyso-PA also suggested that 
this lipid would  be applicable in direct binding studies, and 
we found that [32P]lyso-PA bound directly and specifically to 
GP IIb-IIIa. 
P A  and lyso-PA are generated rapidly and in significant 
quantities upon cellular activation (Exton, 1990). PA levels 
rise within seconds of exposure of platelets to agonists and 
peak between 60 and 120 s. In thrombin-stimulated  platelets, 
approximately 90% of the newly synthesized PA (2-4 nmol/l 
X lo9 platelets)  arises from the sequential generation of  DAG 
by PI-specific phospholipase C and phosphorylation of the 
DAG by DAG kinase, whereas 10% is generated directly by 
phospholipase D-mediated hydrolysis of PC (Huang et al., 
1991). The rate of de MUO synthesis does not change in 
response to thrombin (Neufield and Majerus, 1983). Lyso-PA 
represents approximately 10% of accumulated PA and is 
produced largely by the action of phospholipase A2 on PA 
(Billah et al., 1981). In at  least two situations,  platelet aggre- 
gation can be dissociated from the production of PA via PIPz 
hydrolysis. First, PA  formation from DAG is partially  inhib- 
ited by DAG kinase inhibitors under conditions in which 
platelet aggregation is enhanced (Chaffoy de Courcelles et al., 
1989). Second, platelet aggregation can be inhibited by protein 
kinase C  inhibitors, such as staurosporin, which have no effect 
on  PA production (Watson et al., 1988). Furthermore, when 
added to platelets, both PA (Kroll et al., 1989) and lyso-PA 
(Benton et al., 1982) induce platelet aggregation, apparently 
by receptor-mediated  activation of PI-specific phospholipase 
C. This involvement in stimulus  activation coupling compli- 
cates  efforts to measure a direct effect of exogenous PA on 
GP  IIb-IIIa function. Thus, at  this time  any effects that PA 
may have on the fibrinogen binding activity of GP IIb-IIIa  in 
platelets are unknown. 
Our studies  indicate that fibrinogen binding to  GP IIb-IIIa 
incorporated into PA-containing lipid vesicles is enhanced, 
suggesting that PA  can affect GP IIb-IIIa within a membrane 
environment. However, we have been unable to enhance 
fibrinogen binding to  GP IIb-IIIa by generating PA in isolated 
platelet membranes. These  results may suggest that activation 
of GP IIb-IIIa requires both the release of a negative regulator 
(O’Toole et al., 1991; Steiner et al., 1991) as well as  the action 
of a positive element. The  future combination of approaches 
involving purified GP IIb-IIIa, isolated platelet membranes, 
and whole platelets should potentially allow the elucidation 
of mechanisms of GP IIb-IIIa  activation. 
In summary,  our  results  demonstrate hat PA, lyso-PA, and 
lipid(s) from activated platelets can affect the fibrinogen 
binding properties of purified GP IIb-IIIa.  These lipids may 
directly regulate the binding activity of the glycoprotein or 
the lipids may provide an environment which restores  fibrin- 
ogen binding activity to GP IIb-IIIa. Further studies are 
needed to determine whether the specific lipids identified here 
actually affect the fibrinogen binding capacity or any other 
function of GP IIb-IIIa in whole platelets. However, the 
identification of these lipids, as well as  the specific peptides 
(Du et al., 1991) and antibodies (O’Toole et al., 1990) previ- 
ously described, provide a number of distinct tools to aid  in 
understanding mechanisms and alterations in GP IIb-IIIa 
structure  that allow fibrinogen binding to occur. 
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